Short-term GHRT was effective and safe without increased risk for cancers among real-world adults with growth hormone deficiency.

As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff ...